Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezigdomide + Elranatamab in RRMM
NCT06988488Phase 2Recruiting
- Sponsor
- Celgene Corporation
- Start
- Oct 2025
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of mezigdomide, elranatamab in multiple myeloma (MM), sponsored by Celgene Corporation. Started Oct 2025; status: recruiting.
02
Drugs
mezigdomideelranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06988488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06988488.